6 terminated. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Terminated 6 |
Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) Paltusotine, Placebo - Acromegaly | Phase 3 | Terminated | Crinetics Pharmaceuticals Inc. | 111 | 2021-12-17 | 2026-07-15 |
| A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly Paltusotine, Placebo - Acromegaly | Phase 3 | Terminated | Crinetics Pharmaceuticals Inc. | 58 | 2021-05-12 | 2026-07-15 |
| Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Gallium-68 DOTATOC PET - Pituitary Tumours | Phase 3 | Terminated | Göteborg University | 22 | 2015-01-01 | 2022-03-31 |
| Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly Octreotide - Acromegaly | Phase 3 | Terminated | Endo USA Inc., a Keenova Therapeutics Company | 12 | 2011-02-01 | 2013-09-20 |
| Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly Octreotide Implant, Sandostatin LAR Depot - Acromegaly | Phase 3 | Terminated | Endo USA Inc., a Keenova Therapeutics Company | 169 | 2008-09-01 | 2013-09-27 |
| Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients C2L-OCT-01 PR, 10 or 20 mg, C2L-OCT-01 PR, 20 mg - Acromegaly | Phase 3 | Terminated | Ambrilia Biopharma, Inc. | 40 | 2008-02-01 | 2010-02-09 |
Acromegaly (6) · Pituitary Diseases (1) · Pituitary Neoplasms (1)
Bone Diseases (6) · Bone Diseases, Endocrine (6) · Brain Diseases (6) · Central Nervous System Diseases (6) · Endocrine System Diseases (6) · Hypothalamic Diseases (6) · Musculoskeletal Diseases (6) · Nervous System Diseases (6) · Pituitary Diseases (5) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Hypothalamic Neoplasms (1) · Neoplasms (1)
Octreotide (3)
Crinetics Pharmaceuticals Inc. (2) · Endo USA Inc., a Keenova Therapeutics Company (2) · Ambrilia Biopharma, Inc. (1) · Göteborg University (1)
United States (5) · Hungary (4) · Poland (3) · Serbia (3) · Argentina (2) · Brazil (2) · Bulgaria (2) · France (2) · Germany (2) · Israel (2) · Italy (2) · Russia (2) · Spain (2) · United Kingdom (2) · Belarus (1)